Tetrabenazine Tablet
Product Images NDC 27241-177

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tetrabenazine (NDC 27241-177). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

12.5mg (Tetrabenazine 12 5)

12.5mg (Tetrabenazine 12 5)
This is a medication package of Tetrabenazine Tablets containing 12.5 mg tetrabenazine per tablet. The usual dosage information can be found in the accompanying package insert. The tablets should be stored in a USP tight container at a temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. It is advised not to accept the package if the seal over the bottle opening is missing or broken. The package is child-resistant, and it was marketed by Ajanta Pharma USA Inc. This medication should be kept out of reach of children. The pharmacist should dispense the medication guide to each patient, and the code number is GUJ/DRUGS/G/25/2080.*
FDA Label Image

25mg (Tetrabenazine 25mg)

25mg (Tetrabenazine 25mg)
Each tablet contains 25 mg tetrabenazine. Usual dosage and other relevant information can be found in the accompanying package insert. The tablets can be purchased in a container with 112 tablets, with the NDC number 2724117713. It is recommended to store the tablets at a temperature between 20°C to 25°C (68°F to 77°F), with permitted excursions to 15°C to 30°C (59°F to 86°F). It is advised to dispense the tablets in a USP tight, light-resistant container and not to accept if the seal is broken. The package is child-resistant, and the pharmacist is required to provide the accompanying medication guide to each patient. The product is marketed by Ajanta Pharma USA Inc. and manufactured in India.*
FDA Label Image

Figure1 (Tetrabenazine Figure1)

Figure1 (Tetrabenazine Figure1)
The text describes a chart or graph showing the Chorea Score change over time for a placebo group and a group that received Tetrabenazine. The scores for each group are listed for study weeks 1 to 13. There is also a note indicating that the error bars are + s.e.m. and that *p<0.05 (which likely refers to statistical significance).*
FDA Label Image

Figure2 (Tetrabenazine Figure2)

Figure2 (Tetrabenazine Figure2)
This appears to be a graph or chart representing the cumulative percentage of patients in a treatment group receiving Tetrabenazine vs Placebo, based on their change from baseline in Chorea Score. The chart also shows the change in Total Chorea Score for each treatment group. The different data points are represented using different shapes - Tetrabenazine data points are represented by a straight line, while Placebo data points are represented by a circle. The percentage of patients falling under each data point is also specified.*
FDA Label Image

Structure (Tetrabenazine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.